Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
49
DNLI Quote, Financials, Valuation and Earnings
Last price:
$21.20
Seasonality move
:
-9.94%
Day range:
$20.25 - $21.45
52-week range:
$10.57 - $23.77
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.62x
P/B ratio:
3.57x
Volume:
1.4M
Avg. volume:
1.8M
1-year change:
13.87%
Market cap:
$3.3B
Revenue:
--
EPS (TTM):
-$2.91
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
DNLI
Denali Therapeutics, Inc.
|
$2.7M | -$0.76 | 559.6% | -2.21% | $32.86 |
|
AGEN
Agenus, Inc.
|
$28.1M | -$1.30 | 329.24% | -36.28% | $12.33 |
|
ENOV
Enovis Corp.
|
$582.4M | $0.84 | 2.67% | 1731.46% | $45.18 |
|
MASI
Masimo Corp.
|
$408.3M | $1.47 | 7.02% | 565.51% | $178.60 |
|
PLX
Protalix Biotherapeutics, Inc.
|
$14.2M | -- | 84.91% | -- | $11.00 |
|
TWST
Twist Bioscience Corp.
|
$102M | -$0.52 | 16.07% | -19.61% | $49.89 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
DNLI
Denali Therapeutics, Inc.
|
$21.18 | $32.86 | $3.3B | -- | $0.00 | 0% | 6.62x |
|
AGEN
Agenus, Inc.
|
$3.33 | $12.33 | $120.4M | -- | $0.00 | 0% | 0.84x |
|
ENOV
Enovis Corp.
|
$25.47 | $45.18 | $1.5B | -- | $0.00 | 0% | 0.65x |
|
MASI
Masimo Corp.
|
$175.35 | $178.60 | $9.4B | 116.80x | $0.00 | 0% | 5.54x |
|
PLX
Protalix Biotherapeutics, Inc.
|
$2.88 | $11.00 | $231.6M | 41.44x | $0.00 | 0% | 3.66x |
|
TWST
Twist Bioscience Corp.
|
$46.92 | $49.89 | $2.9B | -- | $0.00 | 0% | 7.26x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
DNLI
Denali Therapeutics, Inc.
|
4.58% | 0.777 | 2.09% | 9.43x |
|
AGEN
Agenus, Inc.
|
510.35% | 4.019 | 285.06% | 0.03x |
|
ENOV
Enovis Corp.
|
47.63% | 0.357 | 88.79% | 0.84x |
|
MASI
Masimo Corp.
|
41.99% | 0.815 | 7.4% | 1.68x |
|
PLX
Protalix Biotherapeutics, Inc.
|
13.39% | -2.030 | 4.58% | 2.00x |
|
TWST
Twist Bioscience Corp.
|
17.69% | 0.525 | 5.04% | 3.09x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
DNLI
Denali Therapeutics, Inc.
|
-$2.9M | -$137.4M | -42.48% | -44.34% | -- | -$105.9M |
|
AGEN
Agenus, Inc.
|
$26.6M | -$4.9M | -39.69% | -- | -16.08% | -$14.7M |
|
ENOV
Enovis Corp.
|
$304.2M | $2.4M | -32.1% | -52.38% | 0.42% | $32.3M |
|
MASI
Masimo Corp.
|
$230.6M | $83.7M | -11.41% | -19.18% | 22.53% | $49.7M |
|
PLX
Protalix Biotherapeutics, Inc.
|
$9.5M | $2.1M | 10.63% | 12.06% | 11.94% | -$4.2M |
|
TWST
Twist Bioscience Corp.
|
$54M | -$32.9M | -14.09% | -16.63% | -31.73% | -$34.8M |
Denali Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns DNLI or AGEN?
Agenus, Inc. has a net margin of -- compared to Denali Therapeutics, Inc.'s net margin of -116.82%. Denali Therapeutics, Inc.'s return on equity of -44.34% beat Agenus, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital DNLIDenali Therapeutics, Inc.-- -$0.74 $970.6M AGENAgenus, Inc.87.85% $1.94 $60.1M -
What do Analysts Say About DNLI or AGEN?
Denali Therapeutics, Inc. has a consensus price target of $32.86, signalling upside risk potential of 55.13%. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 270.37%. Given that Agenus, Inc. has higher upside potential than Denali Therapeutics, Inc., analysts believe Agenus, Inc. is more attractive than Denali Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DNLIDenali Therapeutics, Inc.17 1 0 AGENAgenus, Inc.2 1 0 -
Is DNLI or AGEN More Risky?
Denali Therapeutics, Inc. has a beta of 1.023, which suggesting that the stock is 2.256% more volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.619, suggesting its more volatile than the S&P 500 by 61.86%.
-
Which is a Better Dividend Stock DNLI or AGEN?
Denali Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Denali Therapeutics, Inc. pays -- of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DNLI or AGEN?
Denali Therapeutics, Inc. quarterly revenues are --, which are smaller than Agenus, Inc. quarterly revenues of $30.2M. Denali Therapeutics, Inc.'s net income of -$126.9M is lower than Agenus, Inc.'s net income of $63.9M. Notably, Denali Therapeutics, Inc.'s price-to-earnings ratio is -- while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Denali Therapeutics, Inc. is 6.62x versus 0.84x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DNLIDenali Therapeutics, Inc.6.62x -- -- -$126.9M AGENAgenus, Inc.0.84x -- $30.2M $63.9M
-
Which has Higher Returns DNLI or ENOV?
Enovis Corp. has a net margin of -- compared to Denali Therapeutics, Inc.'s net margin of -90.11%. Denali Therapeutics, Inc.'s return on equity of -44.34% beat Enovis Corp.'s return on equity of -52.38%.
Company Gross Margin Earnings Per Share Invested Capital DNLIDenali Therapeutics, Inc.-- -$0.74 $970.6M ENOVEnovis Corp.52.84% -$9.10 $2.8B -
What do Analysts Say About DNLI or ENOV?
Denali Therapeutics, Inc. has a consensus price target of $32.86, signalling upside risk potential of 55.13%. On the other hand Enovis Corp. has an analysts' consensus of $45.18 which suggests that it could grow by 77.39%. Given that Enovis Corp. has higher upside potential than Denali Therapeutics, Inc., analysts believe Enovis Corp. is more attractive than Denali Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DNLIDenali Therapeutics, Inc.17 1 0 ENOVEnovis Corp.9 1 0 -
Is DNLI or ENOV More Risky?
Denali Therapeutics, Inc. has a beta of 1.023, which suggesting that the stock is 2.256% more volatile than S&P 500. In comparison Enovis Corp. has a beta of 1.285, suggesting its more volatile than the S&P 500 by 28.492%.
-
Which is a Better Dividend Stock DNLI or ENOV?
Denali Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Enovis Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Denali Therapeutics, Inc. pays -- of its earnings as a dividend. Enovis Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DNLI or ENOV?
Denali Therapeutics, Inc. quarterly revenues are --, which are smaller than Enovis Corp. quarterly revenues of $575.8M. Denali Therapeutics, Inc.'s net income of -$126.9M is higher than Enovis Corp.'s net income of -$518.8M. Notably, Denali Therapeutics, Inc.'s price-to-earnings ratio is -- while Enovis Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Denali Therapeutics, Inc. is 6.62x versus 0.65x for Enovis Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DNLIDenali Therapeutics, Inc.6.62x -- -- -$126.9M ENOVEnovis Corp.0.65x -- $575.8M -$518.8M
-
Which has Higher Returns DNLI or MASI?
Masimo Corp. has a net margin of -- compared to Denali Therapeutics, Inc.'s net margin of 14.46%. Denali Therapeutics, Inc.'s return on equity of -44.34% beat Masimo Corp.'s return on equity of -19.18%.
Company Gross Margin Earnings Per Share Invested Capital DNLIDenali Therapeutics, Inc.-- -$0.74 $970.6M MASIMasimo Corp.62.07% -$1.86 $1.4B -
What do Analysts Say About DNLI or MASI?
Denali Therapeutics, Inc. has a consensus price target of $32.86, signalling upside risk potential of 55.13%. On the other hand Masimo Corp. has an analysts' consensus of $178.60 which suggests that it could grow by 1.85%. Given that Denali Therapeutics, Inc. has higher upside potential than Masimo Corp., analysts believe Denali Therapeutics, Inc. is more attractive than Masimo Corp..
Company Buy Ratings Hold Ratings Sell Ratings DNLIDenali Therapeutics, Inc.17 1 0 MASIMasimo Corp.0 7 0 -
Is DNLI or MASI More Risky?
Denali Therapeutics, Inc. has a beta of 1.023, which suggesting that the stock is 2.256% more volatile than S&P 500. In comparison Masimo Corp. has a beta of 1.262, suggesting its more volatile than the S&P 500 by 26.165%.
-
Which is a Better Dividend Stock DNLI or MASI?
Denali Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Denali Therapeutics, Inc. pays -- of its earnings as a dividend. Masimo Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DNLI or MASI?
Denali Therapeutics, Inc. quarterly revenues are --, which are smaller than Masimo Corp. quarterly revenues of $371.5M. Denali Therapeutics, Inc.'s net income of -$126.9M is lower than Masimo Corp.'s net income of $53.7M. Notably, Denali Therapeutics, Inc.'s price-to-earnings ratio is -- while Masimo Corp.'s PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Denali Therapeutics, Inc. is 6.62x versus 5.54x for Masimo Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DNLIDenali Therapeutics, Inc.6.62x -- -- -$126.9M MASIMasimo Corp.5.54x 116.80x $371.5M $53.7M
-
Which has Higher Returns DNLI or PLX?
Protalix Biotherapeutics, Inc. has a net margin of -- compared to Denali Therapeutics, Inc.'s net margin of 13.19%. Denali Therapeutics, Inc.'s return on equity of -44.34% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.
Company Gross Margin Earnings Per Share Invested Capital DNLIDenali Therapeutics, Inc.-- -$0.74 $970.6M PLXProtalix Biotherapeutics, Inc.53.37% $0.03 $61.1M -
What do Analysts Say About DNLI or PLX?
Denali Therapeutics, Inc. has a consensus price target of $32.86, signalling upside risk potential of 55.13%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 281.94%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Denali Therapeutics, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Denali Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DNLIDenali Therapeutics, Inc.17 1 0 PLXProtalix Biotherapeutics, Inc.1 0 0 -
Is DNLI or PLX More Risky?
Denali Therapeutics, Inc. has a beta of 1.023, which suggesting that the stock is 2.256% more volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.206, suggesting its less volatile than the S&P 500 by 120.633%.
-
Which is a Better Dividend Stock DNLI or PLX?
Denali Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Denali Therapeutics, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DNLI or PLX?
Denali Therapeutics, Inc. quarterly revenues are --, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Denali Therapeutics, Inc.'s net income of -$126.9M is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Denali Therapeutics, Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 41.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Denali Therapeutics, Inc. is 6.62x versus 3.66x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DNLIDenali Therapeutics, Inc.6.62x -- -- -$126.9M PLXProtalix Biotherapeutics, Inc.3.66x 41.44x $17.9M $2.4M
-
Which has Higher Returns DNLI or TWST?
Twist Bioscience Corp. has a net margin of -- compared to Denali Therapeutics, Inc.'s net margin of -29.42%. Denali Therapeutics, Inc.'s return on equity of -44.34% beat Twist Bioscience Corp.'s return on equity of -16.63%.
Company Gross Margin Earnings Per Share Invested Capital DNLIDenali Therapeutics, Inc.-- -$0.74 $970.6M TWSTTwist Bioscience Corp.52.05% -$0.50 $554.1M -
What do Analysts Say About DNLI or TWST?
Denali Therapeutics, Inc. has a consensus price target of $32.86, signalling upside risk potential of 55.13%. On the other hand Twist Bioscience Corp. has an analysts' consensus of $49.89 which suggests that it could grow by 6.33%. Given that Denali Therapeutics, Inc. has higher upside potential than Twist Bioscience Corp., analysts believe Denali Therapeutics, Inc. is more attractive than Twist Bioscience Corp..
Company Buy Ratings Hold Ratings Sell Ratings DNLIDenali Therapeutics, Inc.17 1 0 TWSTTwist Bioscience Corp.7 2 0 -
Is DNLI or TWST More Risky?
Denali Therapeutics, Inc. has a beta of 1.023, which suggesting that the stock is 2.256% more volatile than S&P 500. In comparison Twist Bioscience Corp. has a beta of 2.240, suggesting its more volatile than the S&P 500 by 124.046%.
-
Which is a Better Dividend Stock DNLI or TWST?
Denali Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Twist Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Denali Therapeutics, Inc. pays -- of its earnings as a dividend. Twist Bioscience Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DNLI or TWST?
Denali Therapeutics, Inc. quarterly revenues are --, which are smaller than Twist Bioscience Corp. quarterly revenues of $103.7M. Denali Therapeutics, Inc.'s net income of -$126.9M is lower than Twist Bioscience Corp.'s net income of -$30.5M. Notably, Denali Therapeutics, Inc.'s price-to-earnings ratio is -- while Twist Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Denali Therapeutics, Inc. is 6.62x versus 7.26x for Twist Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DNLIDenali Therapeutics, Inc.6.62x -- -- -$126.9M TWSTTwist Bioscience Corp.7.26x -- $103.7M -$30.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
54
AAOI alert for Feb 28
Applied Optoelectronics, Inc. [AAOI] is up 56.96% over the past day.
Buy
90
BNAI alert for Feb 28
Brand Engagement Network, Inc. [BNAI] is up 36.02% over the past day.
Sell
36
WLDN alert for Feb 28
Willdan Group, Inc. [WLDN] is down 25.56% over the past day.
